We report on a 60-year-old man who presented with painless obstructive jaundice, suspicious of hilar cholangiocarcinoma. Positron emission tomography-computed tomography (PET-CT) demonstrated markedly fluorodeoxyglucose-avid bilateral enlarged submandibular masses and extensive hypermetabolic supra-and infra-diaphragmatic lymphadenopathy. Left submandibular excisional biopsy revealed immunoglobulin G4-related systemic disease. Compared with CT or magnetic resonance imaging, fluorine-18 fluorodeoxyglucose PET-CT not only allows whole-body imaging, but also offers metabolic information that helps to reflect disease activity. Fluorine-18 fluorodeoxyglucose PET-CT is a potential useful tool for diagnosis, treatment response assessment, and relapse detection of this systemic disease that is worth further exploration.
INTRODUCTION
T h i s r e p o r t i s o f a m i d d l e -a g e d m a n w i t h immunoglobulin G4-related systemic disease (IgG4-RSD), a new disease entity characterised by numerous IgG4-positive plasma cells and lymphoplasmacytic infiltrates. 1, 2 Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) may play a complementary role in the diagnosis, treatment response assessment, and relapse detection of this systemic disease.
CASE REPORT
A 60-year-old man presented with painless bilateral submandibular masses in October 2010. He found the masses progressively enlarging for the past 3 weeks. He had no previous history of malignancy. Ultrasonography of the neck showed enlarged bilateral submandibular glands with rounded and mildly lobulated contours associated with heterogeneous hypoechoic echo pattern. For the PET-CT, the patient was fasted for 6 hours before intravenous injection of FDG 370 MBq.
Scanning was initiated 60 minutes after administration of FDG. PET-CT images were taken from the head to the proximal thigh with the Discovery LS scanner (GE Healthcare, Amersham, UK) with a spatial resolution of 6.6 mm in the centre of the field of view. Seven bed positions were performed with 3 minutes per bed position. CT was performed for attenuation correction, lesion localisation, and characterisation. The obtained images were reconstructed using the ordered subsets expectation maximisation iterative reconstruction algorithm. The regions of interests were drawn for FDG uptake quantification on visible lesions with increased uptake, and the maximum standardised uptake value (SUV max ) was semiquantitatively analysed with the following equation:
where A represents the decay-and attenuation-corrected activity in tissue (in MBq/ml), ID the injected dose of FDG (in MBq), and BW the patient's body weight (in g).
FDG PET-CT showed diffuse supra-and infradiaphragmatic lymphadenopathy, including enlarged porta-hepatis lymph nodes, with an SUV max of 6.1 ( Figure 1 ). Homogenous mildly increased splenic FDG Figure 1 . Positron emission tomography-computed tomography shows diffuse supra-and infradiaphragmatic lymphadenopathy, including an enlarged porta-hepatis lymph node with a maximum standardised uptake value of 6.1. 
DISCUSSION
IgG4-RSD is characterised by extensive IgG4-positive plasma cells and T-lymphocyte infiltration. 1,2 IgG4-RSD usually affects elderly or middle-aged men. Patients usually have good clinical status with no constitutional symptoms or fever.
3 IgG4-RSD can involve single or multiple organs in the form of mass lesions. Typically, IgG4-RSD involves the pancreas, salivary gland, bile duct, gallbladder, retroperitoneum, kidney, lung, and prostate. 3 Biochemically, high serum IgG, IgG4, and IgE concentrations and abundant IgG4-bearing plasma cell infiltration are the hallmarks of IgG4-RSD. [3] [4] [5] Within the spectrum of IgG4-RSD, autoimmune pancreatitis and Mikulicz's disease are the two most commonly encountered conditions. Autoimmune pancreatitis is closely associated with a variety of extra-pancreatic lesions, such as sialadenitis. 6 In this patient, Küttner's tumour was initially suspected. Küttner's tumour is a fibroinflammatory salivary gland disease involving one or both submandibular glands, which contain IgG4-positve plasmacytes.
7 Both Küttner's tumour and Mikulicz's disease appear to be within the spectrum of IgG4-RSD. 8, 9 Concomitant lymphadenopathy is commonly encountered in IgG4-RSD, especially in the presence of elevation of serum IgG4 and IgE.
This patient shows that FDG PET-CT offers important information about the disease distribution in benign systemic disease. In this patient, PET-CT not only assessed the extent of involvement of this benign systemic disease, but also identified lesions with the highest FDG metabolism so as to guide the site for further biopsy. This patient was initially suspected of having lymphoma based on the PET-CT findings. Unfortunately, it is not always easy to differentiate lymphoma from IgG4-RSD, either radiologically or histologically. Also, lymphoma development during follow-up of IgG4-RSD has been reported. 10 More studies are needed to validate whether IgG4-RSD patients have increased risk of developing lymphoma.
Potentially, FDG PET-CT may play a useful role in treatment monitoring. IgG4-RSD typically shows significant response to steroid therapy. In IgG4-RSD patients, maintenance steroid therapy should be given for at least 3 years to patients with radiological and serological improvement, even if a patient is no longer symptomatic. 11 However, the long-term outcome for IgG4-RSD patients is yet to be determined. For this patient, follow-up PET-CT was done for treatment response assessment and considerable metabolic improvement was noted. By offering a semi-quantitative score (SUV max ), PET-CT can be used to determine the inflammatory disease activity. However, this patient was receiving steroid treatment when he underwent followup PET-CT, which could overestimate the treatment response. To date, there is still no consensus regarding the optimal timing of PET-CT after steroid therapy. The relatively high radiation dose also counteracts liberal use of FDG PET-CT for repeated assessments of nonmalignant disease such as IgG4-RSD.
Elevated serum IgG4 or IgE are often detected in disease relapse. At present, CT, magnetic resonance imaging, and ultrasonography are used to examine patients with suspected relapse by detecting interval lesion enlargement. Nevertheless, relapse can occur in other organs that are not the primary lesion site, 11 which makes the diagnosis of relapse difficult. Since PET-CT enables whole-body imaging, its potential role for detecting disease relapse is worth further exploration. FDG PET-CT may play a complementary role in IgG4-RSD in terms of diagnosis, biopsy site guidance, treatment response assessment, and relapse detection, although its ultimate role in this systemic disease needs to be further validated. Clinicians should be aware of this new disease entity during PET-CT reporting, particularly if the typical scintigraphic pattern is encountered in a suspicious clinical setting.
